Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$10.96
-0.42 (-3.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-430.9M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.4%
↓Gross Margin
74.0%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2098.0%
FCF CAGR
—
FCF margin
-155.5%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $277.1M · net income $-416.4M · FCF $-430.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $277.1M | $277.1M | $201.6M | $13.8M | $26095.32 |
| Net Income | $-416.4M | $-416.4M | $-384.1M | $-400.4M | $-246.5M |
| EBITDA | $-389.4M | $-389.4M | $-349.5M | $-379.3M | $-232.9M |
| EPS | -0.74 | -0.74 | -0.68 | -0.70 | -0.43 |
| Gross Margin | 74.0% | 74.0% | 75.5% | 79.0% | 73.0% |
| Operating Margin | -159.4% | -159.4% | -207.9% | -3392.6% | -1260033.5% |
| Net Margin | -150.3% | -150.3% | -190.5% | -2911.5% | -944804.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.07 | 0.06 | 0.01 |
| Current Ratio | 4.07 | 4.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-430.9M | $-430.9M | $-430.7M | $-499.8M | $-268.6M |
| Returns | |||||
| ROE | -26.4% | -26.4% | -19.5% | -16.8% | -8.9% |
| Valuation | |||||
| P/B | 3.91 | 3.91 | 1.96 | 2.57 | 2.38 |
| Growth & Yield | |||||
| Revenue Growth | 37.5% | 37.5% | 1365.6% | 52604.3% | — |
| EPS Growth | -8.8% | -8.8% | 2.9% | -62.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+41.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.68 → -0.74
Residual
+41.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.